- Initial results from a phase 2a trial of Glaukos Corp. ( NYSE: GKOS ) GLK-301 showed an improvement in the quality of tear film and in quality of vision for dry eye disease.
- The company plans on advancing the candidate into phase 2b.
- In the study, three different dose levels of GLK-301 were givem twice daily and compared to placebo over 28 days.
- GLK-301 uses Glaukos' ( GKOS ) iLution cream-based drug formulations that are applied to the outer surface of the eyelid for transdermal delivery.
- Seeking Alpha's Quant Rating views Glaukos ( GKOS ) as a buy with high marks for profitability and revisions .
For further details see:
Glaukos sees positive data from mid-stage trial of dry eye treatment